Definium Therapeutics (NASDAQ:DFTX) Sets New 52-Week High - Here's Why

Key Points

• Definium Therapeutics (DFTX) reached a new 52-week high of $20.41, trading up about 7.4% on Wednesday with roughly 570,077 shares changing hands.
• Multiple analysts have upgraded or initiated coverage—HC Wainwright lifted its target to $70 and Jefferies started with a Buy at $30—leaving a MarketBeat consensus of Buy and an average price target of $35.70.
• Definium is a clinical-stage biopharma focused on brain-health disorders with lead candidates MM120 (Phase 3 for GAD and ADHD) and DT402 (Phase 2a for autism); it has a market cap of about $2.02 billion, strong liquidity (current and quick ratios ~6.29) and a negative P/E (~-9.53).

Definium Therapeutics, Inc. (NASDAQ:DFTX - Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $20.41 and last traded at $20.40, with a volume of 570077 shares. The stock had previously closed at $18.90.

Analyst Upgrades and Downgrades

Several analysts have issued reports on DFTX shares. HC Wainwright boosted their target price on shares of Definium Therapeutics from $55.00 to $70.00 and gave the company a "buy" rating in a research note on Monday, March 2nd. Needham & Company LLC reiterated a "buy" rating on shares of Definium Therapeutics in a report on Monday, January 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Cantor Fitzgerald reissued an "overweight" rating on shares of Definium Therapeutics in a research note on Monday, February 2nd. Finally, Jefferies Financial Group started coverage on Definium Therapeutics in a research report on Thursday, January 29th. They set a "buy" rating and a $30.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $35.70.

Definium Therapeutics Trading Up 7.4%

The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.29 and a current ratio of 6.29. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -9.53 and a beta of 2.56. The company's 50 day simple moving average is $17.49 and its two-hundred day simple moving average is $14.18.

Institutional Trading of Definium Therapeutics

A number of institutional investors have recently bought and sold shares of DFTX. Commodore Capital LP increased its position in Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company's stock worth $32,450,000 after purchasing an additional 475,000 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Definium Therapeutics by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company's stock worth $22,204,000 after purchasing an additional 828,067 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Definium Therapeutics by 11.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company's stock valued at $23,732,000 after buying an additional 198,878 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Definium Therapeutics by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company's stock valued at $11,252,000 after buying an additional 66,663 shares in the last quarter. Finally, AWM Investment Company Inc. increased its holdings in Definium Therapeutics by 0.6% in the second quarter. AWM Investment Company Inc. now owns 1,215,662 shares of the company's stock worth $7,890,000 after buying an additional 7,500 shares during the last quarter. Institutional investors and hedge funds own 27.91% of the company's stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.